Laura Rosiñol
University of Barcelona
429 Papers
1.5K Citations
Laura Rosiñol is an academic researcher from University of Barcelona. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 55, co-authored 308 publications. Previous affiliations of Laura Rosiñol include National and Kapodistrian University of Athens & Hospital Universitario La Paz.
Chat about Author
Papers
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
María Eugenia Sarasquete,Ramón García-Sanz,Luis Marín,Miguel Alcoceba,María C. Chillón,Ana Balanzategui,Carlos Santamaría,Laura Rosiñol,Javier de la Rubia,Miguel T. Hernandez,Inmaculada Garcia-Navarro,Juan J. Lahuerta,Marcos González,Jesús F. San Miguel +13 more
TL;DR: Individuals homozygous for the T allele had an increased likelihood of developing ONJ, and SNP rs1934951 was significantly associated with a higher risk of ONJ development even after Bonferroni correction.
248
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
Pieter Sonneveld,Hartmut Goldschmidt,Laura Rosiñol,Joan Bladé,Juan José Lahuerta,Michele Cavo,Paola Tacchetti,Elena Zamagni,Michel Attal,Henk M. Lokhorst,Avinash Desai,Andrew Cakana,Kevin Liu,Helgi van de Velde,Dixie-Lee Esseltine,Philippe Moreau +15 more
TL;DR: Bortezomib-based induction results in significant improvements in response and PFS/OS compared with nonbortezOMib- based induction and is generally well tolerated, with a higher rate of peripheral neuropathy but no apparent increase in risk of death during induction.
246
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva,Noemi Puig,Maria-Teresa Cedena,Laura Rosiñol,Lourdes Cordón,María-Belén Vidriales,Leire Burgos,Juan Flores-Montero,Juan Flores-Montero,Luzalba Sanoja-Flores,Luzalba Sanoja-Flores,Lucia Lopez-Anglada,Roberto Maldonado,Javier de la Cruz,Norma C. Gutiérrez,Maria-Jose Calasanz,María-Luisa Martín-Ramos,Ramón García-Sanz,Joaquin Martinez-Lopez,Albert Oriol,M.J. Blanchard,Rafael Rios,Jesús Martín,Rafael Martínez-Martínez,Anna Sureda,Miguel-Teodoro Hernández,Javier de la Rubia,Javier de la Rubia,Isabel Krsnik,José-María Moraleda,Luis Palomera,Joan Bargay,Jacques J.M. van Dongen,Alberto Orfao,Alberto Orfao,Maria-Victoria Mateos,Joan Bladé,Jesús F. San-Miguel,Juan José Lahuerta +38 more
TL;DR: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in multiple myeloma and overcame poor prognostic features at diagnosis, including high-risk cytogenetics.
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
Gema Mateo,M. Angeles Montalbán,María-Belén Vidriales,Juan J. Lahuerta,Maria V. Mateos,Norma C. Gutiérrez,Laura Rosiñol,Laura Montejano,Joan Bladé,Rafael Martínez,Javier de la Rubia,Joaquín Díaz-Mediavilla,Anna Sureda,José M. Ribera,José M. Ojanguren,Felipe de Arriba,Luis Palomera,María José Terol,Alberto Orfao,Jesús F. San Miguel +19 more
TL;DR: This is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
218
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani,Alfred L. Garfall,Niels W.C.J. van de Donk,Hareth Nahi,Jesús F. San-Miguel,Albert Oriol,Laura Rosiñol,Ajai Chari,Manisha Bhutani,Lionel Karlin,Lotfi Benboubker,Lixia Pei,Raluca Verona,Suzette Girgis,Tara Stephenson,Yusri Elsayed,Jeffrey R. Infante,Jenna D. Goldberg,Arnob Banerjee,Maria-Victoria Mateos,Amrita Krishnan +20 more
TL;DR: The MajesTEC-1 study as mentioned in this paper evaluated the safety, tolerability, and preliminary efficacy of teclistamab in patients with relapsed or refractory multiple myeloma.
216